Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells[1].
IC50 & Target
ceramidase[1]
体外研究 (In Vitro)
Ceranib1 produces a dose-dependent decrease in ceramidase activity, with 50% inhibition at 55 and 28 μM in SKOV3 cells[1]. Ceranib1 (24 hours) does not cause significant acute cytotoxicity at concentrations up to at least those used in the ceramidase assay in SKOV3 cells[1]. Ceranib1 prevents the hydrolysis of endogenous ceramide species and reduces intracellular sphingosine and S1P[1]. Ceranib1 (10 nM-10 μM; 72 hours) exhibits antiproliferative activity for SKOV3 cells[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
Cell Line:
SKOV3 cells
Concentration:
10 nM-10 μM (varying concentrations)
Incubation Time:
72 hours
Result:
Inhibited cell proliferation with IC50 values of 3.9 ± 0.3 μM.
分子量
395.45
Formula
C26H21NO3
CAS 号
328076-61-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Draper JM, et al. Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011 Nov;10(11):2052-61.
Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells[1].
IC50 & Target
ceramidase[1]
体外研究 (In Vitro)
Ceranib1 produces a dose-dependent decrease in ceramidase activity, with 50% inhibition at 55 and 28 μM in SKOV3 cells[1]. Ceranib1 (24 hours) does not cause significant acute cytotoxicity at concentrations up to at least those used in the ceramidase assay in SKOV3 cells[1]. Ceranib1 prevents the hydrolysis of endogenous ceramide species and reduces intracellular sphingosine and S1P[1]. Ceranib1 (10 nM-10 μM; 72 hours) exhibits antiproliferative activity for SKOV3 cells[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
Cell Line:
SKOV3 cells
Concentration:
10 nM-10 μM (varying concentrations)
Incubation Time:
72 hours
Result:
Inhibited cell proliferation with IC50 values of 3.9 ± 0.3 μM.
分子量
395.45
Formula
C26H21NO3
CAS 号
328076-61-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Draper JM, et al. Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011 Nov;10(11):2052-61.
Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells[1].
IC50 & Target
ceramidase[1]
体外研究 (In Vitro)
Ceranib1 produces a dose-dependent decrease in ceramidase activity, with 50% inhibition at 55 and 28 μM in SKOV3 cells[1]. Ceranib1 (24 hours) does not cause significant acute cytotoxicity at concentrations up to at least those used in the ceramidase assay in SKOV3 cells[1]. Ceranib1 prevents the hydrolysis of endogenous ceramide species and reduces intracellular sphingosine and S1P[1]. Ceranib1 (10 nM-10 μM; 72 hours) exhibits antiproliferative activity for SKOV3 cells[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
Cell Line:
SKOV3 cells
Concentration:
10 nM-10 μM (varying concentrations)
Incubation Time:
72 hours
Result:
Inhibited cell proliferation with IC50 values of 3.9 ± 0.3 μM.
分子量
395.45
Formula
C26H21NO3
CAS 号
328076-61-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Draper JM, et al. Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011 Nov;10(11):2052-61.
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC50 of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity[1][2].
IC50 & Target
IC50: 28 μM (Ceramidase)[1]
体外研究 (In Vitro)
Ceranib-2 (10 nM-10 µM; 72 hours; SKOV3 cells) treatment inhibits cell proliferation and/or survival with an IC50 value of 0.73 μM[1]. Ceranib-2 (0.75-1.5 µM; 48 hours; SKOV3 cells) treatment causes accumulation of cells in the sub-G1 (apoptosis), G2 and S (0.75 μM only) phases of the cell cycle, concomitant with reductions in the number of cells in G1 phase[1]. Ceranib-2 produces a dose-dependent decrease in ceramidase activity, with 50% inhibition at 28 μM, induces the accumulation of multiple ceramide species, and decreases levels of sphingosine and S1P[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
Cell Line:
SKOV3 cells
Concentration:
10 nM-10 µM
Incubation Time:
72 hours
Result:
Cell proliferation and/or survival were inhibited with an IC50 value of 0.73 μM for Ceranib-2.
Cell Cycle Analysis[1]
Cell Line:
SKOV3 cells
Concentration:
0.75 μM, or 1.5 μM
Incubation Time:
48 hours
Result:
Induced cell-cycle arrest and cell death.
体内研究 (In Vivo)
Ceranib-2 (20-50 mg/kg; intraperitoneal injection; daily for 5 days per week; for 3 weeks; female Balb/c mice) treatment delays tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity[1]. Intraperitoneal administration of 50 mg/kg Ceranib-2 results in progressive increases in its circulating levels, reaching a peak plasma concentration of approximately 40 μM at the 2 hr time point. Ceranib-2 appears to be cleared with a half-life of less than 2 hr[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Female Balb/c mice injected with JC murine mammary adenocarcinoma cells[1]
Dosage:
20 mg/kg or 50 mg/kg
Administration:
Intraperitoneal injection; daily for 5 days per week; for 3 weeks
Result:
Delayed tumor growth in a syngeneic tumor model.
分子量
381.42
Formula
C25H19NO3
CAS 号
1402830-75-4
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Draper JM, et al. Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011 Nov;10(11):2052-61.
[2]. Kus G, et al. Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2. In Vitro Cell Dev Biol Anim. 2015 Nov;51(10):1056-63.
